Cargando…
Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high grade urothelial carcinoma of the bladder
Immunotherapeutic strategies are increasingly used in the treatment of a number of malignancies including high grade urothelial carcinoma (HGUC) of the bladder. Because of this, detailed and accurate assessment of the tumour immune microenvironment is paramount. In this study, we aimed to correlate...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596305/ https://www.ncbi.nlm.nih.gov/pubmed/31485721 http://dx.doi.org/10.1007/s00428-019-02661-2 |
_version_ | 1784600334754119680 |
---|---|
author | Hodgson, Anjelica Jungbluth, Achim A. Katabi, Nora Xu, Bin Downes, Michelle R. |
author_facet | Hodgson, Anjelica Jungbluth, Achim A. Katabi, Nora Xu, Bin Downes, Michelle R. |
author_sort | Hodgson, Anjelica |
collection | PubMed |
description | Immunotherapeutic strategies are increasingly used in the treatment of a number of malignancies including high grade urothelial carcinoma (HGUC) of the bladder. Because of this, detailed and accurate assessment of the tumour immune microenvironment is paramount. In this study, we aimed to correlate the composition of the tumour immune microenvironment with oncologic outcome and the expression of two cancer testis antigens (CTAs), CT10 and PRAME, potential cancer vaccine targets, as well as major histocompatibility complex I (MHC I), a molecule associated with tumour immune escape and resistance to immunotherapy. Triplicate tissue microarrays (TMAs) were constructed using 207 cases of HGUC of the bladder. Oncologic outcome data was gathered for each case. Consecutive sections from the TMA blocks were stained with CD3, CD4, CD8, FOXP3, PD1, PD-L1, CT10, PRAME, and MHC I. 21% and 15% of cases expressed CT10 and PRAME, respectively. 88% of cases showed absent or decreased MHC I expression. CT10-expressing tumours showed a significantly worse disease specific survival (p = 0.007, hazard ratio 2.245, confidence interval 1.223–4.122). CT10, PRAME, and MHC I expression significantly correlated with other some immune parameters. CT10 and PRAME are expressed in a subset of HGUC and CTA and MHC I expression correlate with a number of important immune parameters. Together, these findings highlight the potential for exploring novel immune therapeutic strategies in HGUC. Additional studies evaluating the clinical relevance of these findings are warranted. |
format | Online Article Text |
id | pubmed-8596305 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
record_format | MEDLINE/PubMed |
spelling | pubmed-85963052021-11-17 Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high grade urothelial carcinoma of the bladder Hodgson, Anjelica Jungbluth, Achim A. Katabi, Nora Xu, Bin Downes, Michelle R. Virchows Arch Article Immunotherapeutic strategies are increasingly used in the treatment of a number of malignancies including high grade urothelial carcinoma (HGUC) of the bladder. Because of this, detailed and accurate assessment of the tumour immune microenvironment is paramount. In this study, we aimed to correlate the composition of the tumour immune microenvironment with oncologic outcome and the expression of two cancer testis antigens (CTAs), CT10 and PRAME, potential cancer vaccine targets, as well as major histocompatibility complex I (MHC I), a molecule associated with tumour immune escape and resistance to immunotherapy. Triplicate tissue microarrays (TMAs) were constructed using 207 cases of HGUC of the bladder. Oncologic outcome data was gathered for each case. Consecutive sections from the TMA blocks were stained with CD3, CD4, CD8, FOXP3, PD1, PD-L1, CT10, PRAME, and MHC I. 21% and 15% of cases expressed CT10 and PRAME, respectively. 88% of cases showed absent or decreased MHC I expression. CT10-expressing tumours showed a significantly worse disease specific survival (p = 0.007, hazard ratio 2.245, confidence interval 1.223–4.122). CT10, PRAME, and MHC I expression significantly correlated with other some immune parameters. CT10 and PRAME are expressed in a subset of HGUC and CTA and MHC I expression correlate with a number of important immune parameters. Together, these findings highlight the potential for exploring novel immune therapeutic strategies in HGUC. Additional studies evaluating the clinical relevance of these findings are warranted. 2019-09-02 2020-04 /pmc/articles/PMC8596305/ /pubmed/31485721 http://dx.doi.org/10.1007/s00428-019-02661-2 Text en https://creativecommons.org/licenses/by/4.0/Terms of use and reuse: academic research for non-commercial purposes, see here for full terms. http://www.springer.com/gb/open-access/authors-rights/aam-terms-v1 |
spellingShingle | Article Hodgson, Anjelica Jungbluth, Achim A. Katabi, Nora Xu, Bin Downes, Michelle R. Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high grade urothelial carcinoma of the bladder |
title | Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high grade urothelial carcinoma of the bladder |
title_full | Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high grade urothelial carcinoma of the bladder |
title_fullStr | Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high grade urothelial carcinoma of the bladder |
title_full_unstemmed | Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high grade urothelial carcinoma of the bladder |
title_short | Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high grade urothelial carcinoma of the bladder |
title_sort | evaluation of cancer testis antigen (ct10, prame) and mhc i expression in high grade urothelial carcinoma of the bladder |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596305/ https://www.ncbi.nlm.nih.gov/pubmed/31485721 http://dx.doi.org/10.1007/s00428-019-02661-2 |
work_keys_str_mv | AT hodgsonanjelica evaluationofcancertestisantigenct10prameandmhciexpressioninhighgradeurothelialcarcinomaofthebladder AT jungbluthachima evaluationofcancertestisantigenct10prameandmhciexpressioninhighgradeurothelialcarcinomaofthebladder AT katabinora evaluationofcancertestisantigenct10prameandmhciexpressioninhighgradeurothelialcarcinomaofthebladder AT xubin evaluationofcancertestisantigenct10prameandmhciexpressioninhighgradeurothelialcarcinomaofthebladder AT downesmicheller evaluationofcancertestisantigenct10prameandmhciexpressioninhighgradeurothelialcarcinomaofthebladder |